Journal of Biopharmaceutics, 58, 2004, pp 265-278ĭ40: Experimental details relating to the data filed Lipophilic Drug Substance by Meltrex®-Technology"ĭ35: "Classification of orally administered drugs on the World Health Organization list of Essential Medicines to the biopharmaceutics classification system", Eur. The documents cited during the opposition proceedings included the following:ĭ20: Rosenberg at al., "Meltrex®-FormulationsĬontaining Solid Solutions of Nearly Insoluble Drugs:įormation of Nanoparticles on Dissolution in Water"ĭ21: Rosenberg et al., "Amorphous Embedding of a The present appeal lies from the decision of the opposition division to reject the oppositions. Opponents 01 and 02 withdrew their oppositions on and 14 January 2016 respectively. Four oppositions were filed against the granted patent under Article 100 (a), (b), (c) EPC on the grounds that its subject-matter lacked novelty and inventive step, was not sufficiently disclosed and extended beyond the content of the application as filed. A solid pharmaceutical dosage form which comprises ritonavir and lopinavir, formulated in solid dispersion, said solid dispersion comprising at least one pharmaceutically acceptable water-soluble polymer which has a Tg of at least 50☌ and at least one pharmaceutically acceptable surfactant having an HLB value of from 4 to 10." Independent claim 1 as granted read as follows: 2 258 344 was granted on the basis of a set of 15 claims. Solid pharmaceutical dosage form comprising a ritonavir and lopinavir solid dispersion Documentation of the appeal procedure can be found in the Registerīibliographic information is available in:
0 kommentar(er)
